Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 49 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health Crisis Preparedness Plan MOST POPULAR Study Aims to Reduce Lung Cancer Stigma by Teaching Health Professionals... January 15, 2025 Financial Navigation Can Reduce the Financial Toxicity of Cancer Care April 21, 2023 New option to treat advanced oesophageal cancer approved for NHS in... August 11, 2021 The path to least resistance: How our researchers are outsmarting cancer’s... May 25, 2022 Load more HOT NEWS Cómo los ensayos clínicos pueden llevar a un tratamiento que salve... Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients... Doctors Say Girl Has ‘Vanishing Bones’ That Are Slowly Disappearing From... How the history of medicine influenced our perception of cancer
